Pfizer Inc. (PFE)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
At close: 04:01PM EDT
Pre-Market:
| Previous Close | 29.27 |
| Open | 29.57 |
| Bid | 30.14 x 1000 |
| Ask | 30.12 x 4000 |
| Day's Range | 29.44 - 30.14 |
| 52 Week Range | 25.20 - 34.11 |
| Volume | |
| Avg. Volume | 31,751,116 |
| Market Cap | 170.398B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.46 |
| Earnings Date | Oct 29, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | 1.68 (5.59%) |
| Ex-Dividend Date | Jul 26, 2024 |
| 1y Target Est | 33.01 |
ZacksLilly Gets FDA Approval for Eczema Drug Ebglyss
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
- Investing.com
Midday movers: Intel, Pfizer rise; Apple falls
(Updated - September 16, 2024 11:34 AM EDT)
Business WirePfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting condition that can significantly impact quality of life in affected patients with cancer.ii,iii Results will be presented
© 2024 Yahoo. All rights reserved.